Julian Singer, the son of famed activist investor Paul Singer of Elliott Management, said his JDS1 fund boosted its ownership stake in Catalyst Biosciences Inc (NASDAQ:CBIO) by 53% to 2,014,832 from 1,312,532. In a 13D filing with the US Securities and Exchange Commission, Singer, under the corporate name of JDS1, said he bought the shares because he and a group of other investors on May 9 said they planned to solicit proxies at the company’s 2022 annual meeting. Q1 2022 hedge fund letters, conferences and more Singer and the group nominated three directors, Shelly C. Lombard, Matthew Stecker,…